Bicycle Therapeutics (BCYC) Revenue & Revenue Breakdown
Bicycle Therapeutics Revenue Highlights
Latest Revenue (Y)
$26.98M
Latest Revenue (Q)
$9.36M
Bicycle Therapeutics Revenue by Period
Bicycle Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $26.98M | 86.52% |
2022-12-31 | $14.46M | 23.65% |
2021-12-31 | $11.70M | 12.58% |
2020-12-31 | $10.39M | -24.72% |
2019-12-31 | $13.80M | 93.40% |
2018-12-31 | $7.14M | 246.41% |
2017-12-31 | $2.06M | - |
Bicycle Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $9.36M | -52.04% |
2024-03-31 | $19.52M | 266.14% |
2023-12-31 | $5.33M | -0.39% |
2023-09-30 | $5.35M | -53.04% |
2023-06-30 | $11.40M | 132.78% |
2023-03-31 | $4.90M | 53.72% |
2022-12-31 | $3.19M | 4.77% |
2022-09-30 | $3.04M | -30.56% |
2022-06-30 | $4.38M | 13.42% |
2022-03-31 | $3.86M | 2.36% |
2021-12-31 | $3.77M | -12.97% |
2021-09-30 | $4.33M | 142.75% |
2021-06-30 | $1.78M | -1.27% |
2021-03-31 | $1.81M | -53.01% |
2020-12-31 | $3.85M | 0.16% |
2020-09-30 | $3.84M | 144.56% |
2020-06-30 | $1.57M | 39.15% |
2020-03-31 | $1.13M | -78.62% |
2019-12-31 | $5.28M | 760.10% |
2019-09-30 | $614.00K | -59.66% |
2019-06-30 | $1.52M | -76.16% |
2019-03-31 | $6.38M | 503.97% |
2018-12-31 | $1.06M | -34.35% |
2018-09-30 | $1.61M | -3.07% |
2018-06-30 | $1.66M | -40.85% |
2018-03-31 | $2.81M | 328.70% |
2017-12-31 | $655.00K | - |
Bicycle Therapeutics Revenue Breakdown
Bicycle Therapeutics Revenue Breakdown by Product
Quarterly Revenue by Product
Product/Service | Sep 21 | Mar 21 |
---|---|---|
Target 6 Material Right | $1.10M | - |
Target Four Material Right | - | $300.00K |
Bicycle Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
Country | Sep 21 | Mar 21 |
---|---|---|
Target 6 Material Right | $1.10M | - |
Target Four Material Right | - | $300.00K |
Bicycle Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
MRUS | Merus | $43.95M | $7.33M |
BCYC | Bicycle Therapeutics | $26.98M | $9.36M |
IDYA | IDEAYA Biosciences | $23.39M | - |
ADAG | Adagene | $18.11M | $833.34K |
ANAB | AnaptysBio | $17.16M | $10.97M |
SEER | Seer | $16.66M | $3.07M |
MGTX | MeiraGTx | $14.02M | $282.00K |
STOK | Stoke Therapeutics | $8.78M | $4.22M |
IGMS | IGM Biosciences | $2.13M | $497.00K |
INBX | Inhibrx | $1.80M | - |
FIXX | Q32 Bio | $1.16M | - |
KROS | Keros Therapeutics | $151.00K | $83.00K |
ANEB | Anebulo Pharmaceuticals | - | - |
CGEM | Cullinan Oncology | - | - |
CCCC | C4 Therapeutics | - | - |
ACRV | Acrivon Therapeutics | - | - |
MLYS | Mineralys Therapeutics | - | - |
ORIC | ORIC Pharmaceuticals | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
TNYA | Tenaya Therapeutics | - | - |
BCYC Revenue FAQ
What is Bicycle Therapeutics’s yearly revenue?
Bicycle Therapeutics's yearly revenue for 2023 was $26.98M, representing an increase of 86.52% compared to 2022. The company's yearly revenue for 2022 was $14.46M, representing an increase of 23.65% compared to 2021. BCYC's yearly revenue for 2021 was $11.7M, representing an increase of 12.58% compared to 2020.
What is Bicycle Therapeutics’s quarterly revenue?
Bicycle Therapeutics's quarterly revenue for Q2 2024 was $9.36M, a -52.04% decrease from the previous quarter (Q1 2024), and a -17.86% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $19.52M, a 266.14% increase from the previous quarter (Q4 2023), and a 298.67% increase year-over-year (Q1 2023). BCYC's quarterly revenue for Q4 2023 was $5.33M, a -0.39% decrease from the previous quarter (Q3 2023), and a 67.38% increase year-over-year (Q4 2022).
What is Bicycle Therapeutics’s revenue growth rate?
Bicycle Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 130.62%, and for the last 5 years (2019-2023) was 95.46%.